Caribou Biosciences, Inc. Severance Costs
Caribou Biosciences, Inc. (CRBU) reported Severance Costs of $1.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2026-08-13
- Caribou Biosciences, Inc. severance costs for the quarter ending 2025-12-31 was $0.00.
- Caribou Biosciences, Inc. severance costs for the quarter ending 2025-09-30 was $0.00.
- Caribou Biosciences, Inc. severance costs for fiscal 2025 was $1.84M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 6 month as first filed | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $1.84M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.84M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.84M 10-Q · filed 2026-08-13 | $1.78M 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |